BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Reported here is the final analysis from the phase 1 trial (NCT02081378) [34] assessing the long-term safety, tolerability, and antileukemic activity of asciminib monotherapy in patients with CML-CP without BCR::ABL1T315I after ≥ 2 TKIs with ≤ 8.4 years of exposure.